LUTIKIZUMAB
UNII 15FAZ725S0

Substance Identification & Data

This profile provides standardized clinical and technical data for Lutikizumab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 15FAZ725S0.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 1791411-57-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

15FAZ725S0

CAS Registry Number

1791411-57-8

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

LUTIKIZUMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C166465

National Cancer Institute reference terminology for clinical and research data.

INN ID

10347

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

JK-209

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Lutikizumab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

LUTIKIZUMAB

Common Names & Synonyms

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS IL1A (INTERLEUKIN 1 ALPHA) AND HOMO SAPIENS IL1B (INTERLEUKIN 1 BETA, IL-1B, 1L1F2)), HUMANIZED MONOCLONAL ANTIBODY, TETRAVALENT BISPECIFIC; GAMMA1 HEAVY CHAIN (1-577) (HUMANIZED VH ANTI-IL1B (HOMO SAPIENS IGHV3-23*04 (80.60%) -(IGHD)-IGHJ4*01) (8.8.12) (1-119) -6-MER LINKER (120-125)-HOMO SAPIENS VH ANTI-IL1A (IGHV3-30*03 (88.80%) -(IGHD)-IGHJ1*01) (8.8.15) (126-247) -HOMO SAPIENS IGHG1*01 (CH1 (248- 345), HINGE (346-360), CH2 L1.3>A (364), L1.2>A (365), (361-470), CH3 (471-575), CHS (576-577)) (248-577)), (350-327')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-327') (HUMANIZED V-KAPPA ANTI-IL1B (HOMO SAPIENS IGKV1- 27*01 (82.10%) -IGKJ2*01) (6.3.9) (1'-106') -7-MER LINKER-HOMO SAPIENS V-KAPPA ANTI-IL1A (IGKV1-12*01 (92.60%) -IGKJ4*01) (6.3.9) (114'-220')-HOMO SAPIENS IGKC*01, KM3 (221'-327')); DIMER (356-356:359-359)-BISDISULFIDE

IMMUNOGLOBULIN, ANTI-(INTERLEUKIN 1.BETA./INTERLEUKIN 1.ALPHA.) (SYNTHETIC HUMAN A-1234138 HEAVY CHAIN), DISULFIDE WITH SYNTHETIC HUMAN A-1234138 LIGHT CHAIN, DIMER

LUTIKIZUMAB [INN]

LUTIKIZUMAB [USAN]

LUTIKIZUMAB [WHO-DD]